Results 111 to 120 of about 12,575 (207)

Influence of Darunavir: β-cyclodextrin complex on the solubility of Darunavir

, 2016
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Kogawa, Ana Carolina, Corrêa, Josilene Chaves Ruela, Salgado, Hérida Regina Nunes   +2 more
openaire   +1 more source

Use of darunavir in HIV-infected women during pregnancy

Терапевтический архив, 2013
The use of antiretroviral drugs (ARVDs) in a mother and a child can reduce the risk of vertical transmission of human immunodeficiency virus (HIV) to less than 1%; therefore, highly active antiretroviral therapy is used in all pregnant women regardless ...
L Iu Afonina, E E Voronin
doaj  

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir [PDF]

Reactions Weekly, 2020
openaire   +1 more source

Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals [PDF]

, 2017
Objectives Darunavir is a protease inhibitor that is administered with low-dose ritonavir to enhance its bioavailability. It is prescribed at standard dosage regimens of 600/100 mg twice daily in treatment-experienced patients and 800/100 mg once daily ...
Fischer, M., Rentsch, K., Guidi, M., Fayet-Mello, A., Hösli, I., Csajka, C., Battegay, M., Vernazza, P., Rudin, C., Kahlert, C., Böni, J., Flepp, M., Décosterd, L. A., Bürgisser, P., Nadal, D., Weber, R., Rotger, M., Regenass, S., Karrer, U., Egger, M., Schmid, P., Lubomirov, R., Günthard, H., Fontana, A., Paccaud, F., Francioli, P., Martinetti, G., de Tejada, B. M., Telenti, A., Yerly, S., Hirsch, H. H., Arab-Alameddine, M., Buclin, T., Taffé, P., Hirschel, B., Bernasconi, E., Calmy, A., Kind, C., Trkola, A., Widmer, N., Schultze, D., Cavassini, M., Kaiser, L., Elzi, L., Bucher, H. C., Gorgievski, M., Müller, N., Rauch, A., Ledergerber, B., Fux, C. A., Pantaleo, G., Rickenbach, M., Gatri, M., Schüpbach, J., Furrer, H., Panchaud, A., Cattacin, S., Speck, R., Aouri, M., Klimkait, T., Dubs, R.   +60 more
core  

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection

HIV/AIDS: Research and Palliative Care, 2016
Rustin D Crutchley,1 Rakesh C Guduru,2 Amy M Cheng1 1Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, 2CompanionDX, Houston, TX, USA Abstract: Atazanavir/cobicistat (ATV/c) and darunavir/cobicistat (
Crutchley RD, Guduru RC, Cheng AM,
doaj  

Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study

Drug Design, Development and Therapy, 2019
A Antinori,1 S Rusconi,2 N Gianotti,3 T Bini,4 D Mancusi,5 R Termini51HIV/AIDS Department, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, Rome, Italy; 2Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan,
Antinori A, Rusconi S, Gianotti N, Bini T, Mancusi D, Termini R   +5 more
doaj  

[Desensitization to darunavir in a pediatric patient].

Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993), 2015
Treatment of HIV infection requires the combination of multiple antiretroviral drugs, known as highly active antiretroviral therapy (HAART); however, up to 84% of patients experience adverse drug effects that lead to discontinuation within first months of treatment. Skin manifestations are reported to 22% of patients. The severity of these is variable,
Julio César Cambray-Gutiérrez, Patricia López-Pérez, Aurora Alejandra Chávez-García, Leonel Gerardo Del Rivero-Hernández, Nora Hilda Segura-Méndez   +4 more
openaire   +2 more sources

Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens. [PDF]

Pharmaceutics
Chen L, Wang X, Li L, Yang Y, Liu Y, Chen W.   +5 more
europepmc   +1 more source

Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial. [PDF]

Nat Commun
Català-Moll F, Blázquez-Bondia C, Farré-Badia J, Torres F, Manzardo C, Bonfill E, Curran A, Domingo P, Podzamczer D, Force L, Falcó V, Parera M, Casadellà M, Miró JM, Noguera-Julian M, Paredes R, ADVANZ-4 MISTRAL investigators.   +16 more
europepmc   +1 more source

Effectiveness and safety of darunavir and lopinavir for treating children and adolescents living with HIV: a systematic review. [PDF]

BMC Infect Dis
O'Rourke J, Townsend CL, Milanzi E, Castro H, Collins IJ, Judd A, Jesson J, Leroy V, Penazzato M, Vicari M, Renaud F.   +10 more
europepmc   +1 more source